Evidence map›Paper›PMID 28898756›Full record

ArticleBiomaterials2017

Bioreactor culture duration of engineered constructs influences bone formation by mesenchymal stem cells.

Debika Mitra, Jacklyn Whitehead, Osamu W Yasui, J Kent Leach

Abstract read
In one paragraph

Article in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. [Research progress in three-dimensional-printed bone scaffolds combined with vascularized tissue flaps for segmental bone defect reconstruction].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025
    Review
  4. Article
  5. Immune escape ofFrontiers in cellular and infection microbiology · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Recent Advances in Scaffolds for Guided Bone Regeneration.Biomimetics (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Bone Tissue Engineering in the Treatment of Bone Defects.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Debika MitraDepartment of Biomedical Engineering, University of California, Davis, Davis, CA 95616, USA.
Jacklyn WhiteheadDepartment of Biomedical Engineering, University of California, Davis, Davis, CA 95616, USA.
Osamu W YasuiDepartment of Biomedical Engineering, University of California, Davis, Davis, CA 95616, USA.
J Kent LeachDepartment of Biomedical Engineering, University of California, Davis, Davis, CA 95616, USA; Department of Orthopaedic Surgery, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA. Electronic address: jkleach@ucdavis.edu.
University of California, Davis · US

Funding

Training Program in Biomolecular TechnologyT32GM008799 · NIGMS · UNIVERSITY OF CALIFORNIA DAVIS · PI LEACH, J. KENT · 2002 to 2016
$2.4M
Biomaterial regulation of cell spheroids to synergistically enhance bone healingR01DE025475 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEACH, J. KENT · 2015 to 2019
$1.9M
NIDCR NIH HHS R01 DE025475NIGMS NIH HHS T32 GM008799
6 · The paper itself

Abstract

Perfusion culture of mesenchymal stem cells (MSCs) seeded in biomaterial scaffolds provides nutrients for cell survival, enhances extracellular matrix deposition, and increases osteogenic cell differentiation. However, there is no consensus on the appropriate perfusion duration of cellular constructs in vitro to boost their bone forming capacity in vivo. We investigated this phenomenon by culturing human MSCs in macroporous composite scaffolds in a direct perfusion bioreactor and compared their response to scaffolds in continuous dynamic culture conditions on an XYZ shaker. Cell seeding in continuous perfusion bioreactors resulted in more uniform MSC distribution than static seeding. We observed similar calcium deposition in all composite scaffolds over 21 days of bioreactor culture, regardless of pore size. Compared to scaffolds in dynamic culture, perfused scaffolds exhibited increased DNA content and expression of osteogenic markers up to 14 days in culture that plateaued thereafter. We then evaluated the effect of perfusion culture duration on bone formation when MSC-seeded scaffolds were implanted in a murine ectopic site. Human MSCs persisted in all scaffolds at 2 weeks in vivo, and we observed increased neovascularization in constructs cultured under perfusion for 7 days relative to those cultured for 1 day within each gender. At 8 weeks post-implantation, we observed greater bone volume fraction, bone mineral density, tissue ingrowth, collagen density, and osteoblastic markers in bioreactor constructs cultured for 14 days compared to those cultured for 1 or 7 days, and acellular constructs. Taken together, these data demonstrate that culturing MSCs under perfusion culture for at least 14 days in vitro improves the quantity and quality of bone formation in vivo. This study highlights the need for optimizing in vitro bioreactor culture duration of engineered constructs to achieve the desired level of bone formation.

Indexed as

BioreactorsAnimalsCell DifferentiationCells, CulturedFemaleHumansMaleMesenchymal Stem CellsMiceMicroscopy, Electron, ScanningOsteogenesisTissue EngineeringTissue ScaffoldsBioreactorBone formationComposite scaffoldMesenchymal stem cellsOsteogenic differentiationPerfusion

Identifiers

PMID28898756
PMCPMC5618709
OpenAlexW2751469080

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.